SAFETY AND EFFICACY FINDINGS OF A PHASE 1B/2 STUDY OF NANATINOSTAT PLUS VALGANCICLOVIR FOR TREATMENT OF RELAPSED/REFRACTORY EPSTEIN-BARR VIRUS-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA M Capra; P Scheinberg; J Pereira; B Haverkos; S Spruill; D Strickland; P Porcu;

A GLOBAL PHASE 2 TRIAL OF NANATINOSTAT AND VALGANCICLOVIR IN PATIENTS WITH RELAPSED/REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMAS (NAVAL-1 STAGE 1-2) M Lacerda; R Nair; H Chang; N Goldschmidt; B Haverkos; H Hua; L Zinzani; D Strickland; E González;

NANATINOSTAT WITH OR WITHOUT VALGANCICLOVIR IN PATIENTS WITH RELAPSED/REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMA (NAVAL-1 STAGE 1) M Lacerda; R Nair; H Chang; N Goldschmidt; B Haverkos; H Hua; L Zinzani; D Strickland; E González;